CD8⁺ T Cells Negatively Modulate Ischemia-Induced Angiogenesis in Mice.

Area of Science:

• Immunology
• Vascular Biology
• Pharmacology

Background:

• Peripheral arterial disease (PAD) treatment requires novel angiogenesis strategies.
• CD8+ T cells and their cytokine interferon-gamma (IFN-γ) are implicated in pathobiology.
• Green tea catechin epigallocatechin-3-gallate (EGCG) shows potential for vascular regeneration.

Purpose of the Study:

• Investigate CD8+ T-cell involvement in ischemia-induced angiogenesis.
• Examine EGCG's mechanism in facilitating vascular regeneration.
• Evaluate therapeutic potential for PAD.

Main Methods:

• Used CD8a-/- and IFN-γ-/- knockout mice subjected to hindlimb ischemia.
• Assessed blood flow recovery, molecular markers, and immunostaining.
• Treated wild-type mice with EGCG and supplemented with recombinant IFN-γ.
• Utilized human umbilical vein endothelial cells (HUVECs) for in vitro studies.

Main Results:

• CD8a-/- mice exhibited enhanced blood flow recovery, capillary density, and VEGF levels post-ischemia.
• IFN-γ deficiency mirrored these beneficial effects, which were reversed by IFN-γ supplementation.
• EGCG treatment replicated CD8a-/- effects, modulating signaling pathways and reducing inflammation.
• EGCG inhibited T-cell-induced angiogenesis in HUVECs, reducing NLRP3 and caspase-1.

Conclusions:

• CD8+ T-cell deficiency promotes angiogenesis, suggesting a role in vascular repair.
• EGCG effectively counteracts CD8+ T-cell-mediated negative impacts on angiogenesis.
• These findings support developing immune-inflammatory therapies targeting CD8+ T cells for vascular diseases like PAD.